Gilead Sciences, Inc. $GILD Stock Purchased by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 412.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,418 shares of the biopharmaceutical company’s stock after purchasing an additional 10,799 shares during the period. Provenance Wealth Advisors LLC’s holdings in Gilead Sciences were worth $2,000,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Gilead Sciences during the second quarter valued at about $15,393,785,000. Legal & General Group Plc acquired a new stake in Gilead Sciences during the second quarter worth about $1,316,606,000. Deutsche Bank AG acquired a new stake in Gilead Sciences during the second quarter worth about $918,387,000. Jupiter Topco LLC bought a new position in Gilead Sciences during the second quarter valued at about $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Gilead Sciences during the second quarter valued at about $398,905,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.7%

GILD stock opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The firm has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The business’s 50 day moving average is $151.77 and its 200-day moving average is $140.25. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.47 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Truist Financial boosted their price objective on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Barclays reduced their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a research note on Friday. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.15.

Insider Activity at Gilead Sciences

In other news, CEO Daniel O’Day sold 15,881 shares of the company’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25. Following the sale, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $99,311,195.75. This represents a 2.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 126,881 shares of company stock valued at $19,252,455. Insiders own 0.30% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.